Herriot Tabuteau Sells 29,450 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CEO Herriot Tabuteau sold 29,450 shares of Axsome Therapeutics stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $172.33, for a total value of $5,075,118.50. Following the transaction, the chief executive officer owned 7,229 shares of the company’s stock, valued at $1,245,773.57. This trade represents a 80.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Herriot Tabuteau also recently made the following trade(s):

• On Monday, January 5th, Herriot Tabuteau sold 78,703 shares of Axsome Therapeutics stock. The stock was sold at an average price of $171.28, for a total value of $13,480,249.84.
• On Wednesday, January 7th, Herriot Tabuteau sold 31,261 shares of Axsome Therapeutics stock. The shares were sold at an average price of $170.38, for a total value of $5,326,249.18.
• On Thursday, December 4th, Herriot Tabuteau sold 10,558 shares of Axsome Therapeutics stock. The shares were sold at an average price of $148.18, for a total value of $1,564,484.44.
• On Tuesday, December 2nd, Herriot Tabuteau sold 49,252 shares of Axsome Therapeutics stock. The shares were sold at an average price of $144.59, for a total value of $7,121,346.68.
• On Wednesday, December 3rd, Herriot Tabuteau sold 20,163 shares of Axsome Therapeutics stock. The shares were sold at an average price of $146.94, for a total value of $2,962,751.22.
• On Tuesday, November 4th, Herriot Tabuteau sold 50,459 shares of Axsome Therapeutics stock. The shares were sold at an average price of $133.79, for a total value of $6,750,909.61.
• On Wednesday, November 5th, Herriot Tabuteau sold 21,775 shares of Axsome Therapeutics stock. The stock was sold at an average price of $134.49, for a total transaction of $2,928,519.75.
• On Monday, November 3rd, Herriot Tabuteau sold 91,705 shares of Axsome Therapeutics stock. The shares were sold at an average price of $132.34, for a total transaction of $12,136,239.70.

Axsome Therapeutics Stock Down 1.8%

AXSM opened at $167.55 on Friday. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.50. The company’s 50-day moving average is $150.22 and its 200 day moving average is $127.35. Axsome Therapeutics, Inc. has a fifty-two week low of $79.19 and a fifty-two week high of $184.40. The firm has a market capitalization of $8.45 billion, a P/E ratio of -35.88, a PEG ratio of 9.00 and a beta of 0.44.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). The firm had revenue of $170.99 million during the quarter, compared to the consensus estimate of $162.96 million. Axsome Therapeutics had a negative return on equity of 277.31% and a negative net margin of 40.90%.The firm’s revenue for the quarter was up 63.2% on a year-over-year basis. Research analysts expect that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

AXSM has been the topic of a number of recent analyst reports. Mizuho set a $217.00 price target on Axsome Therapeutics in a report on Wednesday, December 31st. HC Wainwright lifted their target price on Axsome Therapeutics from $185.00 to $200.00 and gave the stock a “buy” rating in a research note on Monday. UBS Group boosted their price target on shares of Axsome Therapeutics from $163.00 to $248.00 and gave the stock a “buy” rating in a report on Tuesday. Morgan Stanley downgraded shares of Axsome Therapeutics from an “overweight” rating to a “reduce” rating in a report on Thursday. Finally, B. Riley initiated coverage on shares of Axsome Therapeutics in a research report on Wednesday, October 1st. They issued a “buy” rating and a $179.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Axsome Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $192.35.

Hedge Funds Weigh In On Axsome Therapeutics

Several large investors have recently modified their holdings of AXSM. Vident Advisory LLC purchased a new stake in shares of Axsome Therapeutics during the 1st quarter valued at approximately $360,000. AQR Capital Management LLC raised its holdings in Axsome Therapeutics by 52.7% during the 1st quarter. AQR Capital Management LLC now owns 58,363 shares of the company’s stock valued at $6,807,000 after acquiring an additional 20,152 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Axsome Therapeutics by 4.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company’s stock valued at $2,557,000 after acquiring an additional 1,002 shares during the period. Jones Financial Companies Lllp lifted its position in shares of Axsome Therapeutics by 2,407.9% during the first quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company’s stock worth $889,000 after acquiring an additional 7,320 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in shares of Axsome Therapeutics by 38.7% in the first quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock worth $35,189,000 after acquiring an additional 84,151 shares during the period. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Trending Headlines about Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright materially raised its 2026 earnings estimates (Q2/Q3/Q4 and FY2026 to a combined $3.72 EPS) and reiterated a Buy with a $200 price objective, signaling expectations for stronger near‑term profitability and supporting higher valuation.
• Positive Sentiment: UBS reiterated its Buy rating on AXSM, reinforcing institutional analyst support that can help underpin demand for the shares. Read More.
• Positive Sentiment: Market commentary points to late‑2025 FDA moves — acceptance of a supplemental filing for AXS‑05 (agitation in Alzheimer’s) and FDA support for an NDA filing for AXS‑12 (narcolepsy) — expanding potential indications and revenue runway. Read More.
• Neutral Sentiment: Morgan Stanley reaffirmed an “equal weight” view but lifted its price target to $204 (from $196), implying upside vs. current levels but stopping short of a buy endorsement. Read More.
• Negative Sentiment: Insider selling: CEO Herriot Tabuteau sold a large block of shares across Jan. 5–7 (totaling roughly 139,414 shares over multiple transactions), leaving him with ~7,229 shares — a >90% reduction in his direct holding. Large, concentrated CEO sales can create near‑term supply pressure and raise investor concerns about optics or liquidity needs. Read More.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.